Who is bridgebio Pharma?

In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Is bridgebio Pharma a good drug for rare heart disease?

July 17 (Reuters) - BridgeBio Pharma Inc's (BBIO.O) experimental drug for a rare heart disease showed significant improvement in patients in a late-stage study, sending its shares surging 65% on Monday.

Does bridgebio's data 'bode well' for other drug companies?

Data from BridgeBio's drug also "bodes well" for other companies developing similar treatments such as Alnylam and Ionis Pharmaceutical (IONS.O), RBC Capital Markets analyst Luca Issi said. BridgeBio plans to submit the data to the U.S. Food and Drug Administration (FDA) by the end of 2023 as part of its marketing application.